Thought control of a computer without brain surgery sounds like science fiction. But Apple apparently thinks it’s close enough to reality to acquire Sonera, a California-based startup that has spent years building non-invasive sensors capable of detecting magnetic signals from the brain and muscles. The deal, which closed in May 2026, quietly surfaced through the European Union’s merger registry. Sonera’s website has since gone dark.
What Sonera actually built
Founded in 2018 by Nishita Deka and Dominic Labanowski while they were students at UC Berkeley, Sonera set out to make brain imaging portable and affordable. Speaking in 2020, Deka described the company’s mission plainly: “We are trying to detect brain activity using cheaper, faster methods that are still high-performance. That’s our north star.”
The core technology relies on magnetic rather than electrical sensors. That distinction matters clinically. Electrical signals from the brain are significantly dampened by the skull, which limits what external sensors can reliably pick up. Magnetic fields are not attenuated in the same way, giving Sonera’s approach a meaningful signal advantage. The company emerged from stealth in 2023 with $11 million in financing and had commercialized its first product, a chip called the S1, designed for muscle sensing, prosthetic control, and potential use in consumer wearables.
How this fits Apple’s health and accessibility ambitions
Apple has been building toward neuro-based input for some time. Earlier demonstrations showed an Apple Vision Pro controlled by thought, but that required a surgically implanted device. Sonera’s technology could, in theory, offer a non-invasive path to similar functionality, which is a significant clinical and regulatory difference.
But the more immediate opportunity may sit on the wrist. Sonera’s S1 chip is designed for neuromuscular sensing, which opens the door to health monitoring applications relevant to conditions like ALS, Parkinson’s disease, or myasthenia gravis. Apple Watch already tracks heart rhythm and blood oxygen. Continuous neuromuscular monitoring would be a meaningful clinical addition, and one where wearable form factor actually makes sense.
The technology also has direct accessibility implications. For users who cannot control devices through touch or voice, reliable thought-based or muscle-based input could change what a smartphone or headset actually is for them.
What remains unclear
Apple has made no public statement about the acquisition, which is consistent with how the company typically handles early-stage technology buys. And some technical questions around Sonera’s approach deserve scrutiny. There is a meaningful difference between detecting true neural signals from within the brain and detecting the muscle contractions that brain activity triggers. The two can be correlated, but they are not the same measurement. How Sonera’s S1 chip handles that distinction, and how Apple intends to characterize it, will matter when clinical or regulatory claims eventually follow.
- Non-invasive magnetic sensing avoids the regulatory and safety barriers of implanted devices
- Potential Apple Watch integration could enable neuromuscular health monitoring at scale
- Prosthetic control applications suggest near-term accessibility use cases
- The technology could support hands-free device control for Vision Pro without surgery
For now, the acquisition signals that Apple is serious about moving neural input from research curiosity to product reality. Whether that arrives first as a health feature, an accessibility tool, or something else entirely is the open question.